UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1004-17
Program Prior Authorization/Notification
Medication Amitiza® (lubiprostone)*, Ibsrela® (tenapanor)*, Linzess® (linaclotide),
Motegrity® (prucalopride), Movantik®*(naloxegol), Symproic®
(naldemedine), Trulance® (plecanatide)*
P&T Approval Date 9/11/2007, 6/10/2008, 6/9/2009, 7/2010, 7/2011, 7/2012, 8/2012,
7/2013, 7/2014, 7/2015, 7/2016, 6/2017, 10/2017, 3/2018, 3/2019,
12/2019, 12/2020, 12/2021, 4/2022, 11/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Amitiza (lubiprostone)* is indicated for the treatment of chronic idiopathic constipation, for opioid
induced constipation in adult patients with chronic non-cancer pain including patients with chronic
pain related to prior cancer or its treatment who do not require frequent (e.g.,weekly) opioid dosage
escalation, and for irritable bowel syndrome with constipation in women aged 18 years and older.
Ibsrela (tenapanor)* is indicated for treatment of irritable bowel syndrome with constipation (IBS-C)
in adults. Linzess (linaclotide) is indicated in adults for the treatment of chronic idiopathic
constipation and irritable bowel syndrome with constipation and for the treatment of functional
constipation (FC) in pediatric patients 6 to 17 years of age. Trulance (plecanatide)* is indicated in
adults for the treatment of chronic idiopathic constipation and irritable bowel syndrome with
constipation. Motegrity (prucalopride) is indicated for the treatment of chronic idiopathic
constipation (CIC) in adults. Movantik (naloxegol)* and Symproic (naldemedine) are opioid
antagonists indicated for the treatment of opioid-induced constipation in adult patients with chronic
non-cancer pain including patients with chronic pain related to prior cancer or its treatment who do
not require frequent (e.g.weekly) opioid dosage escalation. Physicians and patients should
periodically assess the need for continued treatment with these agents.
2. Coverage Criteriaa:
A. Initial Therapy
1. Amitiza* will be approved based on one of the following:
a. Diagnosis of chronic idiopathic constipation
-OR-
b. Both of the following:
(1) Diagnosis of irritable bowel syndrome with constipation
-AND-
(2) Patient was female at birth
-OR-
© 2024 UnitedHealthcare Services, Inc.
1
c. One of the following criteria:
(1) Diagnosis of opioid-induced constipation in patients being treated for chronic,
non-cancer pain
(2) Diagnosis of opioid-induced constipation in patients with chronic pain related to
prior cancer or its treatment who do not require frequent (e.g.,weekly) opioid
dosage escalation.
Authorization will be issued for 12 months
2. Ibsrela* will be approved based on the following criterion:
a. Irritable bowel syndrome with constipation
Authorization will be issued for 12 months
3. Linzess will be approved based on one of the following criteria:
a. Chronic idiopathic constipation
b. Irritable bowel syndrome with constipation
c. Functional constipation
Authorization will be issued for 12 months
4. Trulance* will be approved based on one of the following criteria:
a. Chronic idiopathic constipation
b. Irritable bowel syndrome with constipation
Authorization will be issued for 12 months
5. Motegrity will be approved based on the following criterion:
a. Diagnosis of chronic idiopathic constipation
Authorization will be issued for 12 months
6. Movantik* or Symproic will be approved based on one of the following criteria:
a. Diagnosis of opioid-induced constipation in patients being treated for chronic, non-
cancer pain
b. Diagnosis of opioid-induced constipation in patients with chronic pain related to
prior cancer or its treatment who do not require frequent (e.g., weekly) opioid
dosage escalation.
Authorization will be issued for 12 months
© 2024 UnitedHealthcare Services, Inc.
2
B. Reauthorization
1. Amitiza*, Ibsrela*, Linzess, Motegrity, Movantik*, Symproic, or Trulance* will
be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
* Brand Amitiza, Ibsrela, Movantik and Trulance are typically excluded from coverage.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place
• Step therapy may be in place
• Prior Authorization/Medical Necessity may be in place
4. References:
1. Amitiza [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November
2020.
2. Ibsrela [package insert]. Waltham, MA: Ardelyx, Inc.; April 2022.
3. Linzess [package insert]. North Chicago IL: AbbVie; June 2023
4. Motegrity [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; November
2020.
5. Movantik [package insert]. Wilmington, DE: AstraZeneca Pharmaceutical LP.; April 2020.
6. Symproic [package insert]. Raleigh, NC: BioDelivery Services International, Inc.; July 2021.
7. Trulance [package insert]. Bridgewater, NJ: Bausch Health US, LLC; March 2024.
Program Prior Authorization/Notification – Constipation agents
Change Control
7/2014 Annual review. No changes to the criteria.
10/2014 Modification to implementation date
7/2015 Added appropriate use criteria for Movantik. Updated references.
7/2016 Added HCR gender dysphoria language. Updated references.
6/2017 Added Trulance. Updated references.
10/2017 Updated Movantik and Amitiza criteria. Updated references.
3/2018 Added Symproic to criteria. Updated Trulance criteria based on new
indication for irritable bowel syndrome with constipation.
12/2018 Administrative change to add statement regarding use of automated
processes.
© 2024 UnitedHealthcare Services, Inc.
3
3/2019 Annual review. Added Motegrity and updated references.
12/2019 Added Ibsrela and Zelnorm to criteria.
12/2020 Annual review. Remove Ibsrela since listed as discontinued on FDA
website. Updated references.
12/2021 Annual review. Updated references.
4/2022 Added Ibsrela to criteria.
11/2022 Review. The black box warning of Linzess and Trulance changed the
contraindication from patients less than 18 to patients less than 2 years
of age therefore removed the age restriction. Zelnorm was removed
because discontinued from the market. Added state mandate language.
7/2023 Added new indication for Linzess. Updated references.
7/2024 Annual review. Removed criteria for Ibsrela that patient is 18 or older.
Updated references.
© 2024 UnitedHealthcare Services, Inc.
4